Advanced MRSA Test Receives US FDA Approval
By LabMedica International staff writers Posted on 30 Jan 2014 |
Image: The fully automated BD MAX System (Photo courtesy of Becton, Dickinson and Company).
Clinical laboratories in the United States can now take advantage of a dedicated assay for the rapid diagnosis of MRSA (methicillin-resistant Staphylococus aureus) infections.
The global medical and biotechnological company Becton, Dickinson and Company (Franklin Lakes, NJ, USA) announced that the MAX MRSA XT Assay, which is marketed by their BD Diagnosis subsidiary, had received [US] Food and Drug Administration (FDA) 510(k) approval for use as a diagnostic test.
The MAX MRSA XT Assay is intended for use on the fully automated BD MAX System and complements the MAX StaphSR Assay, which reports results for both Staphylococus aureus (SA) and MRSA.
Both assays employ BD's eXTended Detection Technology to identify a broad range of SA strains including mecA and mecC dropout mutants and new strains of MRSA that may not be detected by other assays.
"Assay design is critical to detect MRSA accurately and ensure appropriate infection control interventions are applied," said Dr. Patrick Murray, worldwide director of scientific affairs at BD Diagnostics. "The BD MAX MRSA XT Assay helps improve patient safety by providing hospitals with a new solution to detect the latest strains of this drug-resistant superbug."
Related Links:
Becton, Dickinson and Company
The global medical and biotechnological company Becton, Dickinson and Company (Franklin Lakes, NJ, USA) announced that the MAX MRSA XT Assay, which is marketed by their BD Diagnosis subsidiary, had received [US] Food and Drug Administration (FDA) 510(k) approval for use as a diagnostic test.
The MAX MRSA XT Assay is intended for use on the fully automated BD MAX System and complements the MAX StaphSR Assay, which reports results for both Staphylococus aureus (SA) and MRSA.
Both assays employ BD's eXTended Detection Technology to identify a broad range of SA strains including mecA and mecC dropout mutants and new strains of MRSA that may not be detected by other assays.
"Assay design is critical to detect MRSA accurately and ensure appropriate infection control interventions are applied," said Dr. Patrick Murray, worldwide director of scientific affairs at BD Diagnostics. "The BD MAX MRSA XT Assay helps improve patient safety by providing hospitals with a new solution to detect the latest strains of this drug-resistant superbug."
Related Links:
Becton, Dickinson and Company
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA